ANIPNasdaqPharmaceutical PreparationsFiscal year ends December 31
ANI PHARMACEUTICALS INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026
$72.56+0.27 (+0.37%)
Close on Oct 19, 2026
- Market cap
- $1.59B
- P/E (TTM)
- 15.4
- Dividend yield
- –
ANI PHARMACEUTICALS INC revenue by segment
By business segment
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rare Disease and Brands | $566.32M | $518.09M | $483.93M | $447.25M | $383.75M | $325.81M | $294.34M | – | – | – | – | – | 57.9% | +47.6% |
| Generics and Other | $412.06M | $405.61M | $399.43M | $379.63M | $363.65M | $348.26M | $320.03M | – | – | – | – | – | 42.1% | +13.3% |
| Generics, Established Brands, and Other | – | – | – | – | – | – | – | $371.15M | $381.34M | $384.74M | $374.70M | $361.44M | – | – |
| Rare Disease | – | – | – | – | – | – | – | $184.31M | $157.61M | $132.72M | $112.12M | $87.96M | – | – |
| Operating income | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rare Disease and Brands | $179.25M | $156.36M | $141.24M | $120.88M | $84.65M | $70.50M | $72.47M | – | – | – | – | – | +111.8% |
| Generics and Other | $145.08M | $146.76M | $154.99M | $146.18M | $143.72M | $135.58M | $116.02M | – | – | – | – | – | +0.9% |
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rare Disease and Brands total net revenues | $566.34M | $518.11M | $483.95M | $447.25M | $383.75M | $325.81M | $294.34M | – | – | – | – | – | 57.9% | +47.6% |
| Rare Disease total net revenues | $479.94M | $448.06M | $422.65M | $378.42M | $316.39M | $261.62M | $229.60M | $184.31M | $157.61M | – | $112.12M | – | 49.1% | +51.7% |
| Generics and Other total net revenues | $412.04M | $405.59M | $399.41M | $379.63M | $363.65M | $348.26M | $320.03M | – | – | – | – | – | 42.1% | +13.3% |
| Cortrophin Gel | $405.53M | $370.05M | $347.78M | $295.75M | $246.45M | $214.00M | $198.09M | $180.43M | $157.61M | – | $112.12M | – | 41.4% | +64.5% |
| Generic pharmaceutical products | $399.59M | $390.83M | $384.11M | $361.95M | $345.80M | $329.47M | $301.00M | $294.23M | $286.60M | $275.95M | $269.45M | $255.64M | 40.8% | +15.6% |
| ILUVIEN and YUTIQ | $74.42M | $78.01M | $74.87M | $82.67M | $69.94M | $47.62M | $31.51M | $3.87M | $0 | – | $0 | – | 7.6% | +6.4% |
| Brands | $47.13M | $48.51M | $61.31M | $68.84M | $67.36M | $64.19M | $64.74M | – | – | – | – | – | 4.8% | -30.0% |
| Unapproved Products | $24.50M | $24.90M | $24.10M | $23.60M | $23.10M | $23.80M | $22.40M | $22.40M | $26.10M | $22.80M | $22.40M | $20.60M | 2.5% | +6.1% |
| Sales of rare disease pharmaceutical products | – | – | – | – | – | – | – | – | $157.61M | $132.72M | $112.12M | $87.96M | – | – |
| Royalties and other pharmaceutical services | – | – | $15.30M | $17.68M | $17.85M | $18.79M | $19.03M | – | – | – | – | – | – | – |
By region
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | – | – | – | – | – | – | $604.99M | $554.24M | $538.95M | $517.46M | $486.25M | $447.60M | – | – |
| Canada | – | – | – | – | – | – | – | – | $0 | $0 | $565.00K | $1.79M | – | – |
| International | – | – | – | – | – | – | $9.39M | – | – | – | $565.00K | – | – | – |
From the segment and revenue-disaggregation notes of Ani Pharmaceuticals's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.